%0 Randomized Controlled Trial
%T A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy.
%A Qian H
%A Chi C
%A Tricard T
%A Zhu Y
%A Dong L
%A Wang Y
%A Sha J
%A Wang J
%A Ma Z
%A Wang Y
%A Liu J
%A Dong B
%A Pan J
%A Xue W
%J J Urol
%V 211
%N 5
%D 2024 May
%M 38591703
%F 7.6
%R 10.1097/JU.0000000000003876
%X <B>UNASSIGNED: </B>Benefits of docetaxel-based neoadjuvant chemohormonal therapy (NCHT) before radical prostatectomy (RP) remain largely unknown. We explored whether docetaxel-based NCHT would bring pathological benefits and improve biochemical progression-free survival (bPFS) over neoadjuvant hormonal therapy (NHT) in locally advanced prostate cancer.<BR><B>UNASSIGNED: </B>A randomized trial was designed recruiting 141 locally advanced, high-risk prostate cancer patients who were randomly assigned at the ratio of 2:1 to the NCHT group (75 mg/m2 body surface area every 3 weeks plus androgen deprivation therapy for 6 cycles) and the NHT group (androgen deprivation therapy for 24 weeks). The primary end point was 3-year bPFS. Secondary end points were pathological response including pathological downstaging and minimal residual disease rates.<BR><B>UNASSIGNED: </B>The NCHT group showed significant benefits in 3-year bPFS compared to the NHT group (29% vs 9.5%, P = .002). At a median follow-up of 53 months, the NCHT group achieved a significantly longer median bPFS time than the NHT group (17 months vs 14 months). No significant differences were found between the 2 groups in pathological downstaging and minimal residual disease rates.<BR><B>UNASSIGNED: </B>NCHT plus RP achieved significant bPFS benefits when compared with NHT plus RP in high-risk, locally advanced prostate cancer. A larger cohort with longer follow-up duration is essential in further investigation.